Recent News

• 11.04.2026 - Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
• 11.03.2026 - Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio
• 10.27.2026 - Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress
• 10.13.2026 - Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress
• 09.08.2026 - Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
• 09.01.2026 - Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
• 08.31.2026 - Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
• 08.04.2026 - Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
• 07.23.2026 - Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
• 06.18.2026 - Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration

Recent Filings

• 11.03.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.03.2026 - 8-K Current report
• 11.03.2026 - EX-99.1 EX-99.1
• 10.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.16.2026 - 144 Report of proposed sale of securities
• 10.15.2026 - 144 Report of proposed sale of securities
• 10.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.25.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors